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INHIBITION OF LIVER, KIDNEY, AND INTESTINE REGENERATION BY RAPAMYCIN, ,2 
For a decade, liver transplant recipients have been treated 
with cyclosporine, a drug with modest hepatotoxicity (1). Con-
cern that CsA might inhibit hepatic regeneration or the ability 
of the transplanted liver to adjust its size to that of the recipient 
prompted studies by Makowka et a1. (2) and others (3-5), 
which showed that regeneration actually was enhanced. A 
newer unrelated immunosuppressive agent, FK506, has the 
same properties (5). In addition, these 2 drugs have other 
actions that are collectively called hepatotrophic. The increase 
in hepatocyte replication that is caused by portacaval shunt in 
dogs is more than doubled by intrahepatic infusion of either of 
these drugs via the tied-off central portal vein, and the expected 
atrophy and organelle disruption is prevented (6, 7). Direct 
experimentation in nude rats has ruled out immune modulation 
of lymphocytes and NK cells as an explanation (8). 
These observations have contributed to a hypothesis that 
CsA and FK506 modify signal transduction in a variety of cells, 
not limited to those of the immune system (7, 9, 10), and 
including signaling pathways associated with growth contro!' If 
this were true, it would explain the remarkable spectrum of 
adverse as well as desired effects of these agents. Important 
elements in this hypothesis included the discovery that the 
cytosolic receptors for FK506 and rapamycin (FK506-binding 
protein, FKBP) and cyclosporine (cyclophilin) are distinct 
proteins that exhibit peptidyl-prolyl cis trans isomerase (rota-
mase) activity (11, 12) and that these small-molecular-weight 
cytoplasmic proteins are in virtually all cells in the body, as 
well as in the nuclei of some (13, 14). 
How these 3 drugs (cyclosporine, FK506, and rapamycin) 
block or modify signaling pathways (15) is not understood. 
Rotamases have been shown to facilitate protein folding (16, 
17) and catalyze the interconversion of rotamers of peptidyl-
prolyl bonds in vitro (18, 19), but the inhibition of this enzy-
matic activity is not related to the action of these drugs on T 
lymphocytes (20). The fact that signal transduction in T-
lymphocytes is blocked in different ways by FK506 and rapa-
mycin (20, 21) is of great interest, particularly because these 2 
drugs are chemically related and have the same binding site 
(FKBP). Consequently, the hepatotrophic qualities of rapa-
mycin were determined with the same dog and rat test models 
as had been used previously to test CsA, FK506 (2-7), and 
recombinant FKBP (22). In addition, the influence of rapa-
mycin on renal and intestinal regeneration was determined. 
The results with rapamycin were profoundly different from 
those observed previously with the other 2 drugs. 
The dogs underwent a completely diverting portacaval shunt. 
Immediately afterwards, an infusion catheter was inserted into 
the tied-off left portal vein for pump-driven constant infusion 
of the rapamycin over the next 4 days in the doses shown in 
Table 1. At the end of 4 days, the animals were injected with 
0.2 MCijkg intravenous 3H thymidine (New England Nuclear, 
Boston), and killed 2 hr later. Specimens were obtained for 
comparison of the hepatocytes in the left (infused) and right 
(not infused) liver lobes using previously described morpho-
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Ayerst Research Company, Princeton, New Jersey. 
metric and autoradiographic techniques (6, 7). There was no 
effect (Table 1) on the hepatocyte atrophy and the increased 
hepatocyte renewal that are characteristic after Eck fistula and 
that are prevented both by cyclosporine (6) and by FK506 (7). 
For the regeneration experiments, fasted adult male inbred 
Fisher 344 rats weighing 180-200 g (Hilltop Lab Animals Inc., 
Scottsdale, P A) were assigned to groups, given water and food 
for 4 days, and treated daily with vehicle or rapamycin. On the 
fourth day, between 0900 and 1030, groups 2-5 underwent 70% 
hepatectomy under light ether anesthesia (5). Rats of groups 7 
and 8 had right nephrectomy (2), and those in group 10 and 11 
had a 40% resection of small intestine excluding the jejunum. 
Twenty-four hr after the operations or control period, 50 MCi-
3H-thymidine was administered by intraperitoneal injection. 
The rats were killed 2 hr later by guillotine. Hepatic DNA 
synthesis and liver mitosis, kidney DNA synthesis and small 
bowel DNA synthesis were performed as described previously 
in cyclosporine and FK506 experiments (5,23). 
Hepatic regeneration was significantly inhibited by RPM 
with a dose relationship so that at 1.0 mg/kg the normal 
response was virtually eliminated (Table 2). Regeneration of 
the kidney and intestine was significantly inhibited with the 
intermediate dose of 0.3 mg/kg/day (Table 3). 
These results add to the significance of the previous dem-
onstration that rapamycin affects T-Iymphocytes differently 
than FK506 (20,21) and lend support to the view ofrapamycin 
as an inhibitor of growth factor receptor-associated signaling 
pathways. Instead of promoting liver regeneration and having 
the other hepatotrophic qualities common to FK506 and cyclo-
sporine, rapamycin was antihepatotrophic. In rats submitted 
to hepatectomy, it inhibited instead of augmenting liver regen-
eration and in dogs submitted to Eck fistula it did not prevent 
the hepatocyte atrophy and organelle disruption that are caused 
by this operation but prevented by cyclosporine(6) and FK506 
(7). The observations in rats constitute the first physiologic 
evidence that the immunophilin network that is thought to be 
pleiotropic in its metabolic, immunologic, and growth control 
actions may be involved in countervailing (opposite effects) 
regulatory processes. Regeneration of the kidney and intestine 
was also retarded by RPM administration, indicating that the 
growth-inhibitory effect of RPM is not liver-specific. 
This suggests that rapamycin, a profound immunosuppres-
sant, also should be examined as an antitumor agent. The 
implications are obvious in general and in transplantation in 
particular. Efforts to treat primary hepatic malignancies by 
total hepatectomy and liver transplantation have been plagued 
by a high rate of tumor recurrence. There might be a possibility 
of treating these patients or others whose extirpative proce-
dures have been done for the reason of malignancy (24) with a 
drug that could prevent both rejection and tumor cell replica-
tion. Striking antineoplastic properties of rapamycin against a 
variety of mouse tumors (25) and against human tumors trans-
planted into nude mice (26, 27) have been described. 
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TABLE 1. Hepatocyte size and mitosis in dogs after ECK fistula with continuous intraportal infusion of rapamycin 
Rapamycin Mitosis (No. labels hepato- Cell size (units)a 
Group No. dogs (mg/kg/ cytes per 1000 hepatocytes)a P P 
day) Right lobe Left lobe Right lobe Left lobe 
1 5 0 4.2±0.33 4.4±0.2 0.1043±0.018 0.1102±0.016 
2 2 0.1 4.2±OA 4.1±0.5 NS 0.1046±0.01 0.1062±0.O8 NS 
3 2 0.5 3.9±0.2 3.9±0.Ol NS 0.1018±0.009 0.1018±0.01 NS 
a Mean ± SD. 
TABLE 2. Effect of preoperative intramuscular rapamycin for 4 days on rat liver regeneration 
Dose/day DNA synthesis % Hepatocytes Group No. rats (mg/kg) Hepatectomy (xI03 c.p.m./ in mitosis P MGDNA) 
1 5 3.5±OA 1.7±0.1 
2 10 70% 185±13.0 33A±3.20 
3 10 0.1 70% 92±8.5 16.8±4.2 <0.05 vs. 2 
4 10 0.3 70% 40±6.2 11.2±3.3 <0.005 vs. 2 
5 10 1.0 70% 3.5±3.5 4.8±0.5 <0.005 vs. 2 
TABLE 3. [3H]-thymidine incorporation in kidney and small intestine from normal, nephrectomized, or small intestine-resected rats treated or 
not treated for 4 preoperative days with rapamycin (0.3 mg/kg/day i.m.) 
DNA synthesis 
Group n Treatment Surgery (XI03/c.p.m./ .p 
mgDNA) 
6 5 Vehicle No 2A±0.2 
7 5 Vehicle Unilateral nephrectomy 3.8±2.3 
8 5 RPM Unilateral nephrectomy 0.5±0.01 <0.0005 vs. 7 
9 5 Vehicle No 17.2±2.3 
10 5 Vehicle 40% Small-intestine re- 62.3±10A 
section 
11 5 RPM 40% Small-intestine re- 29.3±5.1 <0.05 vs. 10 
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